The FDA has approved ENCELTO, the first treatment for macular telangiectasia type 2 (MacTel), a rare degenerative eye disease that gradually impairs central vision. ENCELTO is a surgically implanted device that delivers a steady dose of a neuroprotective protein called CNTF to preserve retinal cells and slow disease progression.
